(Total Views: 110)
Posted On: 09/08/2020 8:27:15 AM
Post# of 106533
HALB Halberd Corporation Research on Covid-19 Treatment Development Begins at ASU
JACKSON CENTER, PA / ACCESSWIRE / September 8, 2020 / Halberd Corporation (OTC PINK:HALB) today announced Arizona State University (ASU) commenced its research work for Halberd Corp. The initial phases of ASU's research focuses on the development of antibodies in support of Halberd's two issued patents and three Covid-19 related provisional patent applications for extracorporeal removal of the virus' antigens from a patient's blood. Those antibodies could be multifaceted, including with regard to other viruses. The research will also focus on neutralizing the effects of antigens and developing one or more therapies.
William A. Hartman, Chairman, President and CEO of Halberd Corporation stated, "ASU has assembled an excellent team of very impressive scientists and researchers. We have every confidence they can deliver the desired results. We are particularly impressed with their focus on Phase 1 of the research."
JACKSON CENTER, PA / ACCESSWIRE / September 8, 2020 / Halberd Corporation (OTC PINK:HALB) today announced Arizona State University (ASU) commenced its research work for Halberd Corp. The initial phases of ASU's research focuses on the development of antibodies in support of Halberd's two issued patents and three Covid-19 related provisional patent applications for extracorporeal removal of the virus' antigens from a patient's blood. Those antibodies could be multifaceted, including with regard to other viruses. The research will also focus on neutralizing the effects of antigens and developing one or more therapies.
William A. Hartman, Chairman, President and CEO of Halberd Corporation stated, "ASU has assembled an excellent team of very impressive scientists and researchers. We have every confidence they can deliver the desired results. We are particularly impressed with their focus on Phase 1 of the research."
(0)
(0)
